Scarica l'app Stockscreener
4.34
1.81%
-0.08
Dopo l'orario di chiusura:
4.57
0.23
+5.30%
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
Oppenheimer Maintains Hold Rating on Cellectar Biosciences with $18.00 Average Price Target - AInvest
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2025 Earnings Call Transcript - MSN
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Cellectar signals NDA submission for iopofosine I-131 in WM by early 2026 amid accelerated approval focus - MSN
Cellectar Biosciences Reports Q2 2025 Financial Results - TipRanks
Cellectar Biosciences Reports Q2 EPS $3.39, Below Consensus $3.70 - AInvest
Cellectar Biosciences Q2 2025 Earnings Report - MarketBeat
Cellectar Biosciences shares fall 1.81% after-hours following Q2 2025 earnings call. - AInvest
Cellectar's 2025 Q2 Earnings Call: Key Contradictions in Phase 3 Trial Strategy and Cost Projections - AInvest
Cellectar to Submit NDA for Iopofosine I-131 in WM by Early 2026, Focuses on Accelerated Approval - AInvest
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN
Earnings call transcript: SelectR Biosciences Q2 2025 reports $5.4M loss - Investing.com
Cellectar Biosciences shares rise 7.47% premarket after reporting positive updates on Iopofosine I 131 and CLR 125. - AInvest
Cellectar Achieves Q2 Loss Reduction, R&D Expenses Drop 67.1% - AInvest
Cellectar Cuts Q2 Losses and Expenses - The Globe and Mail
Cellectar Biosciences Reports Q2 GAAP EPS of -$3.39, Beats Estimate by $0.31, with Cash and Cash Equivalents of $11M as of June 30. - AInvest
Cellectar Biosciences Advances Iopofosine I 131 for WM, CLR 125 for TNBC. - AInvest
Cellectar's Blood Cancer Drug Gets FDA Breakthrough Status, Eyes Accelerated Approval Path - Stock Titan
Cellectar Biosciences, Inc. SEC 10-Q Report - TradingView
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionTrade Risk Report & Weekly Top Gainers Trade List - Newser
Cellectar Biosciences Q2 2025 Earnings Preview: Analysts Expect $-3.66 EPS - AInvest
How to manage a losing position in Cellectar Biosciences Inc.Weekly Earnings Recap & Weekly Return Optimization Alerts - Newser
Published on: 2025-08-13 08:37:11 - Newser
What’s next for Cellectar Biosciences Inc. stock priceIndex Update & Long-Term Growth Plans - Newser
Cellectar Biosciences Inc. stock chart pattern explained2025 Market Overview & Long-Term Growth Portfolio Plans - Newser
Will Cellectar Biosciences Inc. see short term momentumJuly 2025 Short Interest & AI Powered Market Entry Strategies - Newser
How to recover losses in Cellectar Biosciences Inc. stockSummary of Trade Cycles in 5-Year Range - Newser
What moving averages say about Cellectar Biosciences Inc.Free Investment Strategy With Low Risk - Newser
Multi factor analysis applied to Cellectar Biosciences Inc.High Return Trade Roadmap with Setup Filters - Newser
Cellectar Biosciences Inc. stock trend forecastTechnical Trend Forecast for Investors - Newser
What recovery options are there for Cellectar Biosciences Inc.Daily Stock Movement Forecast with Accuracy - Newser
A | What is Cellectar Biosciences, Inc.'s revenue forecastBest ROI Stock Strategies - newsyoung.net
Will a bounce in Cellectar Biosciences Inc. offer an exitPattern Recognition Tool for ROI Investors - Newser
Key metrics from Cellectar Biosciences Inc.’s quarterly dataFree Trade Ready Stock Watch for Short Term - Newser
Cellectar Biosciences reports Q2 financial results, conference call on August 14. - AInvest
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 - Yahoo Finance
Cellectar Biosciences to Unveil Q2 2025 Financial Results and Key Corporate Updates Next Week - Stock Titan
Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc - Barchart.com
Cellectar Biosciences Inc. Shows Early Signs of Technical StrengthInvestment Plan With Growth Optimization Finalized - metal.it
Is it the right time to buy Cellectar Biosciences Inc. stockInvest in stocks with long-term growth potential - Jammu Links News
When is Cellectar Biosciences Inc. stock expected to show significant growthGet real-time updates on market trends - Jammu Links News
Is Cellectar Biosciences Inc. stock overvalued or undervaluedExtraordinary market timing - Jammu Links News
What makes Cellectar Biosciences Inc. stock price move sharplyExceptional profit velocity - Jammu Links News
Published on: 2025-08-03 14:24:10 - Jammu Links News
How does Cellectar Biosciences Inc. generate profit in a changing economyRapid wealth creation - Jammu Links News
What are analysts’ price targets for Cellectar Biosciences Inc. in the next 12 monthsRecord-setting profit potential - Jammu Links News
Is Cellectar Biosciences Inc. a growth stock or a value stockMaximize returns with strategic stock selection - Jammu Links News
Should I hold or sell Cellectar Biosciences Inc. stock in 2025Invest smarter with daily trading signals - Jammu Links News
What are the latest earnings results for Cellectar Biosciences Inc.Get professional advice for portfolio optimization - Jammu Links News
Oragenics' Stock Takes A Hit With New Offering Announcement - Finimize
What’s the recovery path for long term holders of Cellectar Biosciences Inc.Market Momentum and Signal Alerts Suggest Reversal - metal.it
Cellectar Biosciences Inc.’s Price Action Aligns with Quant SignalsFree Stock Market Practical Discussion Forums - beatles.ru
Cellectar Biosciences Inc. Could See a Relief Rally From SupportExit Ready Momentum Stock Watchlist Expanded - metal.it
Screener Results Flag Cellectar Biosciences Inc. as OversoldConsistent Gain Investment Strategies Emerge - metal.it
Published on: 2025-07-29 16:45:28 - metal.it
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):